SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the months of May and June.
On May 15, 2024, at 3:15 p.m. EST, Trey Martin, Chief Executive Officer and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the RBC Healthcare Conference in New York City, NY.
On June 11, 2024, at 1:20 p.m. EST, Trey Martin, Chief Executive Officer and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Healthcare Conference in Miami Beach, FL.
A live webcast of each presentation will be available to all interested parties on the Maravai LifeSciences Investor Relations website, under News & Events, Upcoming events. An archived version of the webcast will also be available on the Maravai website after the event is completed.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
Last Trade: | US$4.42 |
Daily Change: | -0.78 -15.00 |
Daily Volume: | 4,056,473 |
Market Cap: | US$625.650M |
November 07, 2024 November 07, 2024 September 24, 2024 August 28, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB